164 related articles for article (PubMed ID: 32547841)
1. Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting.
Javidnia M; Frasier M; Shoulson I; Turkoz I; Budur K
Innov Clin Neurosci; 2020 Jan; 17(1-3):14-19. PubMed ID: 32547841
[TBL] [Abstract][Full Text] [Related]
2. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
[TBL] [Abstract][Full Text] [Related]
3. Interview with Mark Frasier: a Michael J Fox Foundation perspective on precision medicine in Parkinson's.
Frasier MA
Per Med; 2017 Jan; 14(1):13-15. PubMed ID: 29749821
[TBL] [Abstract][Full Text] [Related]
4. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
Dobrić I
Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's disease and the quest for preclinical diagnosis: an interview with Professor Werner Poewe.
Poewe W
Neurodegener Dis Manag; 2017 Oct; 7(5):273-277. PubMed ID: 29043906
[TBL] [Abstract][Full Text] [Related]
6. Trial designs likely to meet valid long-term Alzheimer's disease progression effects: learning from the past, preparing for the future.
Kemp AS; Grossberg GT; Romano SJ; Arnold DL; Ryan JM; Bullock R; Streiner DL
Int J Alzheimers Dis; 2009 Dec; 2009():. PubMed ID: 20798873
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcome Assessments and Digital Health Technologies Supporting Clinical Trial Endpoints in Early Parkinson's Disease: Roundtable Proceedings and Roadmap for Research.
O'Hanlon CE; Farmer CM; Ryan J; Ernecoff N
Rand Health Q; 2024 Jun; 11(3):1. PubMed ID: 38855392
[TBL] [Abstract][Full Text] [Related]
8. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
[TBL] [Abstract][Full Text] [Related]
9. Japan Parkinson's Progression Markers Initiative (J-PPMI).
Mukai Y; Murata M
Nihon Rinsho; 2017 Jan; 75(1):151-155. PubMed ID: 30566310
[TBL] [Abstract][Full Text] [Related]
10. Enabling breakthroughs in Parkinson's disease with wearable technologies and big data analytics.
Cohen S; Bataille LR; Martig AK
Mhealth; 2016; 2():20. PubMed ID: 28293596
[TBL] [Abstract][Full Text] [Related]
11. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Athauda D; Maclagan K; Skene SS; Bajwa-Joseph M; Letchford D; Chowdhury K; Hibbert S; Budnik N; Zampedri L; Dickson J; Li Y; Aviles-Olmos I; Warner TT; Limousin P; Lees AJ; Greig NH; Tebbs S; Foltynie T
Lancet; 2017 Oct; 390(10103):1664-1675. PubMed ID: 28781108
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease.
Marsili L; Rizzo G; Colosimo C
Front Neurol; 2018; 9():156. PubMed ID: 29628907
[TBL] [Abstract][Full Text] [Related]
13. Prodromal Marker Progression in Idiopathic Rapid Eye Movement Sleep Behavior Disorder: Sample Size for Clinical Trials.
Alotaibi F; Pelletier A; Gagnon JF; Montplaisir JY; Postuma RB
Mov Disord; 2019 Dec; 34(12):1914-1919. PubMed ID: 31571268
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study.
Sommerauer M; Fedorova TD; Hansen AK; Knudsen K; Otto M; Jeppesen J; Frederiksen Y; Blicher JU; Geday J; Nahimi A; Damholdt MF; Brooks DJ; Borghammer P
Brain; 2018 Feb; 141(2):496-504. PubMed ID: 29272343
[TBL] [Abstract][Full Text] [Related]
15. Screening for prodromal Parkinson's disease in the general community: a sleep-based approach.
Postuma RB; Pelletier A; Berg D; Gagnon JF; Escudier F; Montplaisir J
Sleep Med; 2016 May; 21():101-5. PubMed ID: 27448479
[TBL] [Abstract][Full Text] [Related]
16. Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments.
Szabo ST; Kinon BJ; Brannan SK; Krystal AK; van Gerven JM; Mahableshwarkar A; Sachs GS
Innov Clin Neurosci; 2015; 12(3-4):11S-25S. PubMed ID: 25977837
[TBL] [Abstract][Full Text] [Related]
17. Tract-Based Spatial Statistics Reveal Lower White Matter Integrity Specific to Idiopathic Rapid Eye Movement Sleep Behavior Disorder as a Proxy for Prodromal Parkinson's Disease.
Ohlhauser L; Smart CM; Gawryluk JR
J Parkinsons Dis; 2019; 9(4):723-731. PubMed ID: 31498130
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers in Parkinson's disease: a funder's perspective.
Frasier M; Chowdhury S; Eberling J; Sherer T
Biomark Med; 2010 Oct; 4(5):723-9. PubMed ID: 20945984
[TBL] [Abstract][Full Text] [Related]
19. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
20. A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.
Merchant KM; Cedarbaum JM; Brundin P; Dave KD; Eberling J; Espay AJ; Hutten SJ; Javidnia M; Luthman J; Maetzler W; Menalled L; Reimer AN; Stoessl AJ; Weiner DM;
J Parkinsons Dis; 2019; 9(1):31-61. PubMed ID: 30400107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
